Neutralizing activity of intravenous immune globulin products against enterovirus D68 strains isolated in Japan.
Enterovirus D68
IVIG
Japan
Neutralization activity
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
18 Jul 2023
18 Jul 2023
Historique:
received:
10
03
2023
accepted:
28
06
2023
medline:
21
7
2023
pubmed:
19
7
2023
entrez:
18
7
2023
Statut:
epublish
Résumé
Enterovirus D68 (EV-D68), belonging to Enterovirus D, is a unique human enterovirus mainly associated with common respiratory diseases. However, EV-D68 can cause severe respiratory diseases, and EV-D68 endemic is epidemiologically linked to current global epidemic of acute flaccid myelitis. In this study, we measured neutralizing antibody titers against six clinical EV-D68 isolates in nine intravenous immune globulin (IVIG) products commercially available in Japan to assess their potential as therapeutic options for severe EV-D68 infection. Seven IVIG products manufactured from Japanese donors contained high neutralizing antibody titers (IC High levels of EV-D68-neutralizing antibodies in IVIG products manufactured from Japanese donors suggest that anti-EV-D68 antibodies are maintained in the Japanese donor population similarly as found in foreign blood donors. Apparent differences in neutralizing antibody titers against the six EV-D68 strains suggest distinct antigenicity among the strains used in this study regardless of the genetic similarity of EV-D68.
Sections du résumé
BACKGROUND
BACKGROUND
Enterovirus D68 (EV-D68), belonging to Enterovirus D, is a unique human enterovirus mainly associated with common respiratory diseases. However, EV-D68 can cause severe respiratory diseases, and EV-D68 endemic is epidemiologically linked to current global epidemic of acute flaccid myelitis.
METHODS
METHODS
In this study, we measured neutralizing antibody titers against six clinical EV-D68 isolates in nine intravenous immune globulin (IVIG) products commercially available in Japan to assess their potential as therapeutic options for severe EV-D68 infection.
RESULTS
RESULTS
Seven IVIG products manufactured from Japanese donors contained high neutralizing antibody titers (IC
CONCLUSIONS
CONCLUSIONS
High levels of EV-D68-neutralizing antibodies in IVIG products manufactured from Japanese donors suggest that anti-EV-D68 antibodies are maintained in the Japanese donor population similarly as found in foreign blood donors. Apparent differences in neutralizing antibody titers against the six EV-D68 strains suggest distinct antigenicity among the strains used in this study regardless of the genetic similarity of EV-D68.
Identifiants
pubmed: 37464326
doi: 10.1186/s12879-023-08429-z
pii: 10.1186/s12879-023-08429-z
pmc: PMC10394975
doi:
Substances chimiques
Antibodies, Neutralizing
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481Subventions
Organisme : the Ministry of Health, Labour and Welfare of Japan
ID : H28-Shinkogyosei-Ippan-007
Organisme : the Japan Agency for Medical Research and Development
ID : 19fk0108084j0001
Organisme : the Ministry of Education, Culture, Sports, Science, and Technology in Japan
ID : 19H03626
Informations de copyright
© 2023. The Author(s).
Références
Clin Infect Dis. 2016 Sep 15;63(6):737-745
pubmed: 27318332
PLoS One. 2017 Sep 13;12(9):e0184335
pubmed: 28902862
J Clin Virol. 2015 Aug;69:172-5
pubmed: 26209401
Front Neurol. 2020 May 22;11:360
pubmed: 32528396
mBio. 2019 Aug 13;10(4):
pubmed: 31409689
Infect Dis (Lond). 2018 Apr;50(4):303-312
pubmed: 29119851
Emerg Microbes Infect. 2017 May 10;6(5):e32
pubmed: 28487560
Emerg Infect Dis. 2016 Aug;22(8):1387-94
pubmed: 27434186
Am J Epidemiol. 1967 Mar;85(2):297-310
pubmed: 4960233
Emerg Infect Dis. 2015 Nov;21(11):1966-72
pubmed: 26485714
J Infect. 2018 Jun;76(6):563-569
pubmed: 29428227
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0022722
pubmed: 35894595
Sci Immunol. 2020 Jul 3;5(49):
pubmed: 32620559
Viruses. 2019 May 29;11(6):
pubmed: 31146373
mBio. 2019 Apr 2;10(2):
pubmed: 30940708
Brain Dev. 2019 May;41(5):443-451
pubmed: 30594353
Sci Transl Med. 2021 Mar 10;13(584):
pubmed: 33692131
MMWR Morb Mortal Wkly Rep. 2014 Sep 12;63(36):798-9
pubmed: 25211545
Pediatr Infect Dis J. 2021 Jan;40(1):6-10
pubmed: 32947598
Pediatr Int. 2019 Aug;61(8):768-776
pubmed: 31136073
J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S49-S53
pubmed: 30590621
MMWR Surveill Summ. 2006 Sep 15;55(8):1-20
pubmed: 16971890
J Infect Dis. 2017 Dec 5;216(10):1245-1253
pubmed: 28968718
Emerg Infect Dis. 2019 Mar;25(3):573-576
pubmed: 30602120
MMWR Morb Mortal Wkly Rep. 2015 Jan 9;63(53):1243-4
pubmed: 25577990
Int J Infect Dis. 2021 May;106:36-40
pubmed: 33771675
J Virol. 2014 Mar;88(5):2374-84
pubmed: 24371050
Euro Surveill. 2019 Aug;24(35):
pubmed: 31481149
Nat Med. 2019 Nov;25(11):1748-1752
pubmed: 31636453
MMWR Morb Mortal Wkly Rep. 2014 Oct 10;63(40):901-2
pubmed: 25299607
Viruses. 2019 Sep 04;11(9):
pubmed: 31487952
Emerg Infect Dis. 2020 Oct;26(10):
pubmed: 32833616
Clin Infect Dis. 2018 Feb 10;66(5):653-664
pubmed: 29028962
Microbiol Immunol. 2012 Feb;56(2):139-43
pubmed: 22309616
PLoS One. 2020 Mar 10;15(3):e0230180
pubmed: 32155216
BMC Med. 2015 Sep 17;13:226
pubmed: 26381232
Emerg Infect Dis. 2019 Mar;25(3):585-588
pubmed: 30789123
Lancet Infect Dis. 2018 Aug;18(8):e239-e247
pubmed: 29482893
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337448
Lancet Infect Dis. 2016 May;16(5):e64-e75
pubmed: 26929196
Nat Rev Microbiol. 2018 Jun;16(6):368-381
pubmed: 29626210
Eur J Pediatr. 2019 Sep;178(9):1305-1315
pubmed: 31338675
J Med Virol. 2022 Jun;94(6):2607-2612
pubmed: 34617599
Eur J Paediatr Neurol. 2019 Mar;23(2):235-239
pubmed: 30670331